Tag: bispecific antibody
Zanidatamab Plus Chemotherapy Shows 56% Improvement in HER2+ Gastric Cancer
Zanidatamab plus chemotherapy reduced disease progression risk by 44% compared to trastuzumab in HER2-positive gastroesophageal cancer patients. The phase III…
Submit Your Paper to GMJ
No APC until January 2027.